🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Feasibility and Interest of the 3D Ephemeris for Temporal Orientation in Alzheimer's: Pilot Study

Recruitingn/aAges 65 Years - anyAllAssistance Publique - Hôpitaux de Paris
NCT06824142 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In geriatric care, occupational therapists use validated tools to assess abilities and performance, identifying deficiencies and proposing rehabilitation programs. Temporal orientation disorders are common, with studies showing that individuals who make mistakes in identifying time are at higher risk of dementia. Temporal orientation issues typically precede spatial orientation problems in Alzheimer's, especially in hospital settings where environmental cues are lost. Maintaining temporal orientation during hospitalization is crucial. While no effective rehabilitation tool currently exists, a new prototype has been developed to address temporal orientation disorders in Alzheimer's and dementia patients, with plans for further evaluation. Main Objective Evaluate in real-life conditions the effectiveness of an adapted external aid, such as the Ephéméride 3D tool, in improving temporal ori

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient ≥ 65 years old. * Patient presenting with temporal orientation impairment during the MMSE test. * Patient with an MMSE score above 20 (mild stage) or a score between 10 and 20 (moderate stage). * Patient who has not expressed any objection. Exclusion Criteria: * Presence of one or more disruptive behavioral disorders. * Presence of confusion of unknown origin. * Visual blindness. * Inability to read or understand French.
💊

What it tests

  • Evaluate in real-life conditions the effectiveness of an adapted external aid as a tool to support temporal orientation rehabilitation for individuals with Alzheimer's disease or related dementias in
📍

Where

1 site
Hôpital Georges Clemenceau
Champcueil, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy